In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.

Published Date: 26 Jan 2024

Researchers recommend that high-risk patients be given consideration for intensification.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.

2.

For treatment, the majority of cancer patients choose complementary therapies.

3.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

4.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot